Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory CLL/SLL: Additional patients and extended follow-up from BRUIN

被引：0

作者：

Munir, Talha ^{[1
]}

Mato, Anthony R. ^{[2
]}

Woyach, Jennifer A. ^{[3
]}

Brown, Jennifer R. ^{[4
,5
]}

Ghia, Paolo ^{[6
,7
]}

Patel, Krish ^{[8
]}

Eyre, Toby A. ^{[9
]}

Lech-Maranda, Ewa ^{[10
]}

Lamanna, Nicole ^{[11
]}

Tam, Constantine S. ^{[12
,13
]}

Seymour, John F. ^{[12
,13
]}

Shah, Nirav N. ^{[14
]}

Coombs, Catherine C. ^{[15
]}

Ujjani, Chaitra S. ^{[16
]}

Patel, Manish R. ^{[17
]}

Fakhri, Bita ^{[18
]}

Cheah, Chan Y. ^{[19
,20
]}

Alencar, Alvaro J. ^{[21
]}

Cohen, Jonathon B. ^{[22
]}

Gerson, James N. ^{[23
]}

Flinn, Ian W. ^{[24
]}

Ma, Shuo ^{[25
]}

Jagadeesh, Deepa ^{[26
]}

Rhodes, Joanna M. ^{[27
]}

Hernandez-Ilizaliturri, Francisco ^{[28
]}

Zinzani, Pier Luigi ^{[29
]}

Balbas, Minna ^{[30
]}

Nair, Binoj ^{[30
]}

Abada, Paolo ^{[30
]}

Wang, Chunxiao ^{[31
]}

Wang, Denise ^{[30
]}

Tsai, Donald E. ^{[30
]}

Wierda, William G. ^{[32
]}

Jurczak, Wojciech ^{[33
]}

机构：

[1] St James Hosp, Leeds, W Yorkshire, England

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Ohio State Univ, Comprehens Canc Ctr, Columbus, OH USA

[4] Dana Farber Canc Inst, Boston, MA USA

[5] Harvard Med Sch, Boston, MA USA

[6] Univ Vita Salute San Raffaele, Milan, Italy

[7] IRCCS Osped San Raffaele, Milan, Italy

[8] Swedish Canc Inst, Ctr Blood Disorders & Cellular Therapy, Seattle, WA USA

[9] Oxford Univ Hosp NHS Fdn Trust, Churchill Canc Ctr, Oxford, England

[10] Inst Hematol & Transfus Med, Warsaw, Poland

[11] Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA

[12] Peter MacCallum Canc Ctr, Melbourne, Australia

[13] Univ Melbourne, Melbourne, Australia

[14] Med Coll Wisconsin, Milwaukee, WI USA

[15] Univ North Carolina Chapel Hill, Chapel Hill, NC USA

[16] Univ Washington, Fred Hutchinson Canc Ctr, Seattle, WA USA

[17] Florida Canc Specialists Sarah Cannon Res Inst, Sarasota, FL USA

[18] Univ Calif San Francisco, San Francisco, CA USA

[19] Linear Clin Res, Perth, Australia

[20] Sir Charles Gairdner Hosp, Perth, Australia

[21] Univ Miami, Miller Sch Med, Miami, FL USA

[22] Emory Univ, Winship Canc Inst, Atlanta, GA USA

[23] Univ Penn, Lymphoma Program, Abramson Canc Ctr, Philadelphia, PA USA

[24] Sarah Cannon Res Inst, Nashville, TN USA

[25] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Div Hematol Oncol, Feinberg Sch Med, Chicago, IL USA

[26] Cleveland Clin, Cleveland, OH USA

[27] Northwell Hlth, Northwell Hlth Canc Inst, Donald & Barbara Zucker Sch Med Hofstra, New Hyde Pk, NY USA

[28] Roswell Pk Comprehens Canc Ctr, Lymphoma Sect, Dept Med Oncol, Buffalo, NY USA

[29] Univ Bologna, Inst Hematol Seragnoli, Bologna, Italy

[30] Loxo Lilly, Indianapolis, IN USA

[31] Eli Lilly & Co, Indianapolis, IN USA

[32] MD Anderson Canc Ctr, Houston, TX USA

[33] Maria Sklodowska Curie Natl Res Inst Oncol, Krakow, Poland

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH23-PO84

引用

页码：110 / 111

页数：2

共 50 条

[1] Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Mato, Anthony R.
Woyach, Jennifer A.
Brown, Jennifer R.
Ghia, Paolo
Patel, Krish
Eyre, Toby A.
Munir, Talha
Lech-Maranda, Ewa
Lamanna, Nicole
Tam, Constantine S.
Seymour, John F.
Shah, Nirav N.
Coombs, Catherine C.
Ujjani, Chaitra S.
Patel, Manish R.
Fakhri, Bita
Cheah, Chan Y.
Alencar, Alvaro J.
Cohen, Jonathon B.
Gerson, James N.
Flinn, Ian W.
Ma, Shuo
Jagadeesh, Deepa
Rhodes, Joanna M.
Hernandez-Ilizaliturri, Francisco
Zinzani, Pier Luigi
Balbas, Minna
Nair, Binoj
Abada, Paolo B.
Wang, Chunxiao
Wang, Denise
Tsai, Donald E.
Wierda, William G.
Jurczak, Wojciech
BLOOD, 2022, 140 : 2316 - 2320
[2] Pirtobrutinib efficacy in covalent BTK-inhibitor pre-treated relapsed/refractory mantle cell lymphoma: Extended follow-up from BRUIN
Lewis, David John
Wang, Michael L.
Shah, Nirav N.
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan Y.
Ujjani, Chaitra S.
Koh, Youngil
Izutzu, Koji
Gerson, James N.
Flinn, Ian
Tessoulin, Benoit
Alencar, Alvaro J.
Ma, Shuo
Lech-Maranda, Ewa
Rhodes, Joanna
Patel, Krish
Woyach, Jennifer
Lamanna, Nicole
Wang, Yucai
Tam, Constantine
Seymour, John F.
Munir, Talha
Nagai, Hirokazu
Hernandez-Ilizaliturri, Francisco
Kumar, Anita
Zelenetz, Andrew
Jain, Preteesh
Nair, Binoj
Tsai, Donald E.
Balbas, Minna
Walgren, Richard A.
Abada, Paolo
Wang, Chunxiao
Zhao, Junjie
Mato, Anthony R.
BRITISH JOURNAL OF HAEMATOLOGY, 2023, 201 : 108 - 109
[3] Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
Wang, Michael L.
Shah, Nirav N.
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan Y.
Ujjani, Chaitra S.
Koh, Youngil
Izutsu, Koji
Gerson, James N.
Flinn, Ian W.
Tessoulin, Benoit
Alencar, Alvaro J.
Ma, Shuo
Lech-Maranda, Ewa
Rhodes, Joanna M.
Patel, Krish
Woyach, Jennifer A.
Lamanna, Nicole
Wang, Yucai
Tam, Constantine S.
Seymour, John F.
Munir, Talha
Nagai, Hirokazu
Hernandez-Ilizaliturri, Francisco
Kumar, Anita
Zelenetz, Andrew D.
Jain, Preetesh
Nair, Binoj
Tsai, Donald E.
Balbas, Minna
Walgren, Richard A.
Abada, Paolo B.
Wang, Chunxiao
Zhao, Junjie
Mato, Anthony R.
BLOOD, 2022, 140 : 9368 - 9372
[4] Efficacy of Pirtobrutinib in BTK-Inhibitor Pre-treated Relapsed/ Refractory CLL/SLL: Phase 1/2 BRUIN Study Results by Prior BCL2-Inhibitor Therapy
Woyach, Jennifer A.
Brown, Jennifer R.
Ghia, Paolo
Roeker, Lindsey E.
Patel, Krish
Eyre, Toby A.
Munir, Talha
Lech-Maranda, Ewa
Lamanna, Nicole
Tam, Constantine S.
Seymour, John
Shah, Nirav N.
Ujjani, Chaitra
Fahkri, Bita
Coombs, Catherine C.
Flinn, Ian
Patel, Manisha R.
Nasta, Sunita D.
Cohen, Jonathon B.
Alencar, Alvaro J.
Cheah, Chan Y.
Ma, Shuo
Rhoades, Joanna M.
Jagadeesh, Deepa
Zinzani, Pier Luigi
Osterborg, Anders
Izutsu, Koji
Tsai, Donald E.
Abada, Paolo
Balbas, Minna
Ruppert, Amy S.
Li, Jian
Jurczak, Wojciech
Wierda, William G.
Stilgenbauer, Stephan
ONCOLOGY RESEARCH AND TREATMENT, 2024, 47 : 118 - 119
[5] Pirtobrutinib in covalent BTK-inhibitor pre- treated relapsed/refractory (R/R) Mantle Cell Lymphoma
Fileni, Caroline
Sarkozy, Clementine
BULLETIN DU CANCER, 2023, 110 (10) : 988 - 990
[6] Genomic evolution and resistance to pirtobrutinib in covalent BTK-inhibitor pre-treated chronic lymphocytic leukemia patients: results from the phase I/II BRUIN Study
Brown, Jennifer
Desikan, Sai Prasad
Nguyen, Bastien
Won, Helen
Tantawy, Shady I.
McNeely, Samuel C.
Marella, Narasimha
Ebata, Kevin
Woyach, Jennifer
Patel, Krish
Tam, Constantine S.
Eyre, Toby A.
Cheah, Chan Y.
Shah, Nirav
Ghia, Paolo
Jurczak, Wojciech
Balbas, Minna
Nair, Binoj
Abada, Paolo
Wang, Chunxiao
Wang, Denise
Mato, Anthony
Gandhi, Varsha
Wierda, William
LEUKEMIA & LYMPHOMA, 2023, 64 : S25 - S26
[7] Genomic Evolution and Resistance during Pirtobrutinib Therapy in Covalent BTK-Inhibitor (cBTKi) Pre-Treated Chronic Lymphocytic Leukemia Patients: Updated Analysis from the BRUIN Study
Brown, Jennifer R.
Desikan, Sai Prasad
Nguyen, Bastien
Won, Helen
Tantawy, Shady I.
McNeely, Samuel
Marella, Narasimha
Ebata, Kevin
Woyach, Jennifer A.
Patel, Krish
Tam, Constantine S.
Eyre, Toby A.
Cheah, Chan Y.
Shah, Nirav N.
Ghia, Paolo
Jurczak, Wojciech
Balbas, Minna
Nair, Binoj
Abada, Paolo
Wang, Chunxiao
Wang, Ying
Roeker, Lindsey E.
Gandhi, Varsha
Wierda, William G.
BLOOD, 2023, 142
[8] Pirtobrutinib in Relapsed/Refractory CLL/SLL: Results From BTK-Naive Cohort in the Phase 1/2 BRUIN Study
Wierda, William G.
Eyre, Toby A.
Lech-Maranda, Ewa
Roeker, Lindsey E.
Patel, Manish
Fukuhara, Noriko
Woyach, Jennifer A.
Brown, Jennifer R.
Patel, Krish
Tam, Constantine S.
Fahkri, Bita
Abada, Paolo
Tsai, Donald E.
Sizelove, Richard
Jurczak, Wojciech
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 : S350 - S350
[9] Pirtobrutinib in covalent BTK-inhibitor (cBTKi) pre-treated mantle cell lymphoma (MCL): Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment.
Shah, Nirav Niranjan
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan
Ujjani, Chaitra Shankar
Izutsu, Koji
Ma, Shuo
Flinn, Ian W.
Alencar, Alvaro Jose
Lewis, David John
Patel, Krish
Maddocks, Kami J.
Wang, Yucai
Munir, Talha
Zelenetz, Andrew David
Balbas, Minna
Tsai, Donald E.
Wang, Chunxiao
Wang, Michael
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[10] Pirtobrutinib in Covalent BTK Inhibitor Pre-Treated Mantle Cell Lymphoma: Updated Results and Subgroup Analysis from the Phase 1/2 BRUIN Study With >3 Years Follow-Up from Start of Enrollment
Wang, Michael L.
Shah, Nirav N.
Jurczak, Wojciech
Zinzani, Pier Luigi
Eyre, Toby A.
Cheah, Chan Y.
Ujjani, Chaitra S.
Izutsu, Koji
Ma, Shuo
Flinn, Ian
Alencar, Alvaro J.
Lewis, David
Patel, Krish
Maddocks, Kami
Wang, Yucai
Munir, Talha
Zelenetz, Andrew D.
Balbas, Minna
Tsai, Donald E.
Wang, Chunxiao
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S459 - S459

← 1 2 3 4 5 →